首页 / 院系成果 / 成果详情页

Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study 期刊论文

编号：

fe699bd4-9d9d-4824-a035-795cd220acbb
作者：

Li, MengXia#^[1]He, Hao#^[1]Ruan, ZhiHua^[3];Zhu, YuXi^[4];Li, RongQing^[5];He, Xiao^[1];Lan, BaoHua^[1];Zhang, ZhiMin^[1];Liu, GuoDong^[6];Xiao, HuaLiang^[7];Wu, Yan^[1];Zhu, Bo^[2];Wang, Ge^[1];Yang, ZhenZhou*^[1]
语种：

英文
期刊：

BMC CANCER ISSN：1471-2407 2017 年 17 卷 ; APR 4
收录：
关键词：

EGFR-TKIs Erlotinib Gefitinib NSCLC EGFR mutation
摘要：

Background: Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib as first-line treatment for CNS metastasis NSCLC patients with EGFR-sensitizing mutations is yet to be elucidated.
Methods: A retrospective analysis was done on cerebral metastasis rate after erlotinib or gefitinib as first-line treatment for advanced NSCLC patients with EGFR-sensitizing mutations. Time to neurological progression (nTTP) and median progression-free survival (mPFS) were calculated.
Results: The study involved 279 patients (erlotinib group: 108, gefitinib group: 171). After a median follow-up of 22 months, 27 patients (25%) in the erlotinib group and 60 patients (35.1%) in the gefitinib group showed CNS progression. The HR of CNS progression for erlotinib versus gefitinib was 0.695 [95% confidence interval (CI), 0.406-1.190], suggesting a risk reduction of 30.5% although not achieving statistical significance. The 6-, 12-and 18-month cumulative CNS progression rates were 0.9, 3.7 and 12% for erlotinib compared with corresponding rates of 5.8, 9.4 and 17% for gefitinib (P = 0.181). However, for those patients with preexisting brain metastases prior to EGFR-TKI treatment, erlotinib as first line treatment significantly extended the median nTTP in comparison to gefitinib (30 months vs 15.8 months, p = 0.024).
Conclusions: Our data show that nTTP can be effectively extended in preexisting brain metastases patients with EGFR-sensitizing mutations initially treated with erlotinib compared with gefitinib. If confirmed, our results indicate that erlotinib may play an important role in controlling CNS progression from EGFR mutation-positive NSCLC.
推荐引用方式
GB/T 7714：

Li Meng-Xia,He Hao,Ruan Zhi-Hua, et al. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study [J].BMC CANCER,2017,17.
APA：

Li Meng-Xia,He Hao,Ruan Zhi-Hua,Zhu Yu-Xi,&Yang Zhen-Zhou.(2017).Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study .BMC CANCER,17.
MLA：

Li Meng-Xia, et al. "Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study" .BMC CANCER 17(2017).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：52  下载次数：0

分享到：

浏览次数：52

下载次数：0

打印次数：0